DANIEL TEMPLE: Open Payments
NPI 1093167520 · CAPITOLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$727 in 34 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $727
Food & beverage: $727
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $157 |
| Novo Nordisk Inc | 4 | $102 |
| Lilly USA, LLC | 4 | $97 |
| Astellas Pharma US Inc | 4 | $87 |
| PFIZER INC. | 4 | $69 |
| Abbott Laboratories | 3 | $66 |
| ABBVIE INC. | 3 | $63 |
| Ardelyx, Inc. | 2 | $32 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Dexcom, Inc. | 1 | $25 |
Products named: Veozah, MOUNJARO, AIRSUPRA, FARXIGA, FREESTYLE LIBRE 3, Ozempic, NURTEC ODT, UBRELVY.
Industry payments across CA — which companies pay providers there.
